Canabigerol (CBG) shows potential in the treatment of atopic dermatitis, study indicates

A study published in MDPI investigated the effects of cannabigerol (CBG) in the treatment of atopic dermatitis (AD), a chronic inflammatory skin condition. Researchers analyzed cellular models and experiments with mice, noting that the compound reduced inflammatory markers and improved the integrity of the skin barrier.

CBG reduces inflammation and improves clinical condition

The tests were conducted on human keratinocytes (HaCaT cells) treated with CBG, where scientists observed a reduction in the expression of inflammatory cytokines, such as IL-1B, IL-6, and TNF. In animal models, mice treated with CBG showed a significant improvement in the severity of dermatitis, with reduced epidermal thickness and a lower count of mast cells - cells associated with allergic reactions.

Furthermore, molecular analyses indicated that CBG modulated the JAK-STAT pathway, one of the main mechanisms involved in AD inflammation. The compound also reduced the activation of NF-κB, a transcription factor linked to an exacerbated immune response.

Perspectives for new treatments

The study suggests that CBG may be a promising candidate for the development of topical therapies aimed at inflammatory skin diseases. Despite the positive results, researchers emphasize the need for further clinical investigations to confirm the efficacy and safety of the compound in humans.

Atopic dermatitis affects millions of people worldwide and is associated with genetic and environmental factors. Conventional treatments, such as corticosteroids and immunosuppressants, can cause adverse effects when used long-term, increasing interest in safer therapeutic alternatives.

The research reinforces the growing scientific attention to non-psychoactive cannabinoids, such as CBG, and their potential in managing inflammatory diseases.